Literature DB >> 1501415

The sodium retaining effects of cyclosporine.

D L Ciresi1, M A Lloyd, S M Sandberg, D M Heublein, B S Edwards.   

Abstract

The effect of chronic cyclosporine administration on volume regulation was studied in mongrel dogs. Dogs received either cyclosporine (20 mg/kg/day p.o.; N = 7) or vehicle (N = 6) while being maintained on a constant sodium diet. Dogs had measurement of baseline vasoactive hormones. Daily sodium excretion was determined. Following eight days of drug administration, dogs were anesthetized, pre-volume expansion data was collected, and dogs underwent a one hour, 10% body weight 0.9% saline volume expansion. Daily sodium balance was +8.6 +/- 2.2 mEq in the cyclosporine group versus 0.4 +/- 1.8 mEq (P less than 0.05) in the control group after 8 days. Prior to acute volume expansion, aldosterone was 22.5 +/- 7.1 ng% in the cyclosporine group versus 4.7 +/- 0.7 ng% in controls (P less than 0.05). ANF was suppressed in the animals receiving cyclosporine. In response to volume expansion, the cyclosporine group demonstrated an attenuation of maximum urine flow by 56%, fractional excretion of sodium by 52%, and electrolyte free water clearance by 75% when compared to controls (P less than 0.05). We demonstrate that chronic cyclosporine administration activates the renin-angiotensin-aldosterone system, suppresses circulating ANF, and results in chronic sodium retention. Additionally, cyclosporine attenuates the natriuretic and diuretic response to acute volume expansion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501415     DOI: 10.1038/ki.1992.231

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  The effect of immunosuppressive drug cyclosporine A on myeloid-derived suppressor cells in transplanted mice.

Authors:  Chenlu Han; Tingting Wu; Ning Na; Yang Zhao; Weiguo Li; Yong Zhao
Journal:  Inflamm Res       Date:  2016-05-04       Impact factor: 4.575

Review 2.  Hypertension after renal transplantation.

Authors:  V Schwenger; M Zeier; E Ritz
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

3.  Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol.

Authors:  Jing Wang; Zhi-Ren Zhang; Chu-Fang Chou; You-You Liang; Yuchun Gu; He-Ping Ma
Journal:  Am J Physiol Renal Physiol       Date:  2008-12-17

Review 4.  Hypertension after kidney transplantation: a pathophysiologic approach.

Authors:  Beje Thomas; David J Taber; Titte R Srinivas
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

Review 5.  Pathogenesis of calcineurin inhibitor-induced hypertension.

Authors:  Ewout J Hoorn; Stephen B Walsh; James A McCormick; Robert Zietse; Robert J Unwin; David H Ellison
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

6.  Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.

Authors:  Giovanna Castoldi; Raffaella Carletti; Silvia Ippolito; Massimiliano Colzani; Francesca Barzaghi; Andrea Stella; Gianpaolo Zerbini; Gianluca Perseghin; Giovanni Zatti; Cira R T di Gioia
Journal:  Acta Diabetol       Date:  2021-03-24       Impact factor: 4.280

Review 7.  Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.

Authors:  Tim Nuttall; Douglas Reece; Elizabeth Roberts
Journal:  Vet Rec       Date:  2014-03       Impact factor: 2.695

8.  Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.

Authors:  Kenichi Ishizawa; Qin Wang; Jinping Li; Osamu Yamazaki; Yoshifuru Tamura; Yoshihide Fujigaki; Shunya Uchida; Richard P Lifton; Shigeru Shibata
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

9.  Apocynin and catalase prevent hypertension and kidney injury in Cyclosporine A-induced nephrotoxicity in rats.

Authors:  Yong Chia Tan; Munavvar Abdul Sattar; Ahmad F Ahmeda; Nurzalina Abdul Karim Khan; Vikneswaran Murugaiyah; Ashfaq Ahmad; Zurina Hassan; Gurjeet Kaur; Mohammed Hadi Abdulla; Edward James Johns
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.